Clinical Trial Search

Primary: Hemagglutination Inhibition Antibody (HIA) Titer for Each of the Three Antigens Contained in the Vaccine — 269.7; 337.3; 288.5; 297.1 Titers

Primary: Safety (Adverse Events) — 8; 6; 0; 0 Participants

Primary: Change in Preference- Subjective Liking Ratings for Each Beverage on a Scale — -12.8; -12.0; -12.6 units on a scale

Primary: Total Recovery (Urine + Feces) of the Administered Radioactivity — 83.2 percentage of radioactivity

Primary: Scores on the Lure Generalization Index (a Behavioral Measure of Generalization) — .24; .26; .14; .10 units on a scale — p=<.046

Primary: Positive Findings for Hereditary Cancer Syndromes — 28; 8; 4; 787 Participants

Primary: Number of Participants With Advance Care Planning Documentation — 0; 1163; 349; 901 Participants — p=<0.05

Primary: Percent Predicted Forced Expiratory Volume in One Second (FEV1) Among Participants With Evidence of Partial Function — 74.8; 76 percent of predicted FEV1

Primary: Assess Inflammatory Response to Intravenous Endotoxin — 167.53; 111.05; 254.92; 128.73 pg/ml

Primary: Change in Clinician-Completed Congenital DM1 Rating Scale (CDM1-RS) — -1.65; -3.40 score on a scale — p=0.0514

Primary: Proportion of Participants Who Achieved and Maintained Reduction in Serum Uric Acid (sUA) < 6 Milligrams Per Deciliter (mg/dL) for At Least 80% of The Time During…

Primary: Number of Participants Who Experienced at Least One Adverse Events (AEs) — 208 Participants

Primary: Percentage of Time Spent in the Combination of Slow Wave Sleep (SWS) and Rapid Eye Movement (REM) Sleep — 43.0; 41.8 Percentage of total sleep time — p=0.0350

Primary: Wound Surface Area Reduction of Radiation Dermatitis Grade 2-3 Wound Size From Baseline to Day 14 (+/- 3 Days) — 10.3; 25.3; 0.5; 4.1 cm^2

Primary: Number of Participants With BAX 888-Related Adverse Events (AEs) — 2; 2 Participants